ArticleAnnals of surgical oncology2025
Recurrence Incidence and Optimal Surveillance After Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Mucinous Appendix Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe optimal surveillance for mucinous appendix cancer (MAC) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) remains unclear. We identified postoperative periods reflecting significant changes in recurrence probability.
methodsA prospective database (1998-2024) of patients with stage IV MAC with low-grade (LGMCP), high-grade (HGMCP), and signet-ring cell (SRC) histology treated with initial complete (CC-0/1) CRS/HIPEC was analyzed. A piecewise exponential recurrence-free survival model was employed. Excluding the first 6 months, postoperative follow-up was divided into periods by forwardly selected knots using minimal Bayesian Information Criterion (BIC) in an adjusted Cox regression. Per-period cumulative recurrence risk (CRR) was calculated by histology. Optimal surveillance was modeled based on 5% CRR changes.
resultsOf 385 patients, 60.3% had LGMCP, 20.8% HGMCP, and 19.0% SRC. Median age was 54 years, 64.9% were female, and median peritoneal cancer index was 26. Median follow-up was 92 months. Knots at 16 and 48 months (BIC = 484.4) defined three periods: I (6-16 months), II (16-48 months), and III (48-120 months). The CRR was highest in period I: 1.0, 2.6, and 3.8 per 10 person-years for LGMCP, HGMCP, and SRC, respectively. The CRR in period II was 0.5, 2.9, and 3.5 and in period III was 0.4, 0.5, and 1.8, respectively. Optimal surveillance occurs every 5.5, 8, and 18 months for LGMCP and every 2-2.5, 4, and 24 months for HGMCP in periods I-III, respectively.
conclusionMucinous appendix cancer exhibits a distinct recurrence probability by histology and key post-CRS/HIPEC periods, which can be addressed by a tailored surveillance schedule.
Indexed as
Identifiers
40924246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.